Syndax Pharmaceuticals
SNDX
72 hedge funds and large institutions have $146M invested in Syndax Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 21 reducing their positions, and 11 closing their positions.
194% more call options, than puts
Call options by funds: $3.6M | Put options by funds: $1.23M
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
14% more capital invested
Capital invested by funds: $128M → $146M (+$18.4M)
0% more funds holding
Funds holding: 72 → 72 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 21
1.72% less ownership
Funds ownership: 63.16% → 61.44% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$468K |
| 2 |
CCIA
Campbell & Co Investment Adviser
Baltimore,
Maryland
|
+$329K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$300K |
| 4 |
Goldman Sachs
New York
|
+$289K |
| 5 |
Two Sigma Investments
New York
|
+$282K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$1.82M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.81M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$1.1M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$578K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$439K |
SNDX Hedge Fund Activity: Q4 2019 in Review
72 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q4 2019, worth a combined $146M — up 14% from $128M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SNDX positions and 11 closed out — a net gain of 5 holders — while 21 added to existing stakes and 21 trimmed.
The largest buyer was D.E. Shaw & Co, opening a new position worth an estimated $468K. The largest seller was Sofinnova Investments, exiting entirely with an estimated $1.82M sold.
- 72 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $146M of Syndax Pharmaceuticals stock for Q4 2019, up 14% quarter-over-quarter.
- 16 funds opened new Syndax Pharmaceuticals positions in Q4 2019 and 11 closed out, a net change of +5 holders.
- The largest Syndax Pharmaceuticals buyer in Q4 2019 was D.E. Shaw & Co, an estimated $468K added.
- The largest Syndax Pharmaceuticals seller in Q4 2019 was Sofinnova Investments, an estimated $1.82M sold.
Based on aggregated 13F filings for Q4 2019.